{"formats":[{"name":"JSON","format":"json","url":"\/downloads\/2026\/code-json\/32.1-162.31_1.json"},{"name":"Plain Text","format":"text","url":"\/downloads\/2026\/code-text\/32.1-162.31_1.txt"},{"name":"XML","format":"xml","url":"\/downloads\/2026\/code-xml\/32.1-162.31_1.xml"},{"name":"HTML","format":"html","url":"\/downloads\/2026\/code-html\/32.1-162.31_1.html"}],"law_id":359164,"edition_id":2,"section_id":359164,"structure_id":51378,"section_number":"32.1-162.31:1","catch_line":"Florence Neal Cooper Smith Sickle Cell Research Endowment Fund","history":"2025, c. 415.","full_text":"A\n\nFrom such funds as may be appropriated by the General Assembly and any gifts, grants, or donations from public or private sources, there is created in the state treasury a special, nonreverting, revolving, and permanent fund to be known as the Florence Neal Cooper Smith Sickle Cell Research Endowment Fund. The Fund shall be established on the books of the Comptroller and shall be administered and implemented by the Board in accordance with the provisions of this section. All funds appropriated for the Fund and any grants, donations, or other assistance provided shall be paid into the state treasury and credited to the Fund. Interest earned on moneys in the Fund shall remain in the Fund and be credited to it. Any moneys remaining in the Fund, including interest thereon, at the end of each fiscal year shall not revert to the general fund but shall remain in the Fund. Moneys in the Fund shall be used solely for the purpose of making grant payments pursuant to this section. Expenditures and disbursements from the Fund shall be made by the State Treasurer on warrants issued by the Comptroller upon written request signed by the chairman or vice-chairman of the Board.\n\nB\n\nMoneys in the Fund shall be used solely to support medical and biomedical sickle cell disease research conducted in institutions of higher education in the Commonwealth that relates to the causes and cures of sickle cell disease.\n\nC\n\nAny appropriations, grants, donations, or other assistance provided pursuant to this section shall be awarded in accordance with the Board’s specific criteria and procedures, requirements for submission of research proposals, and evaluation mechanisms established pursuant to this chapter. However, no requirement for matching funds shall apply to the appropriations, grants, donations, or other assistance awarded to the Fund, and the leveraging of funds is incidental to the support provided under this section. The appropriations, grants, donations, or other assistance provided pursuant to this section may, upon demonstrating a reasonable justification to the Board’s satisfaction, be awarded to support sickle cell disease research that is not eligible for federal research funds through the National Institutes of Health. No moneys from the Fund may be provided to any entity that conducts human sickle cell disease research from stem cells obtained from human embryos or for conducting such research; however, research conducted using stem cells other than embryonic stem cells may be funded.\n\n","order_by":null,"text":{"0":{"id":1336179,"text":"From such funds as may be appropriated by the General Assembly and any gifts, grants, or donations from public or private sources, there is created in the state treasury a special, nonreverting, revolving, and permanent fund to be known as the Florence Neal Cooper Smith Sickle Cell Research Endowment Fund. The Fund shall be established on the books of the Comptroller and shall be administered and implemented by the Board in accordance with the provisions of this section. All funds appropriated for the Fund and any grants, donations, or other assistance provided shall be paid into the state treasury and credited to the Fund. Interest earned on moneys in the Fund shall remain in the Fund and be credited to it. Any moneys remaining in the Fund, including interest thereon, at the end of each fiscal year shall not revert to the general fund but shall remain in the Fund. Moneys in the Fund shall be used solely for the purpose of making grant payments pursuant to this section. Expenditures and disbursements from the Fund shall be made by the State Treasurer on warrants issued by the Comptroller upon written request signed by the chairman or vice-chairman of the Board.","type":"section","prefixes":["A"],"prefix":"A","entire_prefix":"A","prefix_anchor":"A","level":1,"next_prefix":"B"},"1":{"id":1336180,"text":"Moneys in the Fund shall be used solely to support medical and biomedical sickle cell disease research conducted in institutions of higher education in the Commonwealth that relates to the causes and cures of sickle cell disease.","type":"section","prefixes":["B"],"prefix":"B","entire_prefix":"B","prefix_anchor":"B","level":1,"prior_prefix":"A","next_prefix":"C"},"2":{"id":1336181,"text":"Any appropriations, grants, donations, or other assistance provided pursuant to this section shall be awarded in accordance with the Board’s specific criteria and procedures, requirements for submission of research proposals, and evaluation mechanisms established pursuant to this chapter. However, no requirement for matching funds shall apply to the appropriations, grants, donations, or other assistance awarded to the Fund, and the leveraging of funds is incidental to the support provided under this section. The appropriations, grants, donations, or other assistance provided pursuant to this section may, upon demonstrating a reasonable justification to the Board’s satisfaction, be awarded to support sickle cell disease research that is not eligible for federal research funds through the National Institutes of Health. No moneys from the Fund may be provided to any entity that conducts human sickle cell disease research from stem cells obtained from human embryos or for conducting such research; however, research conducted using stem cells other than embryonic stem cells may be funded.","type":"section","prefixes":["C"],"prefix":"C","entire_prefix":"C","prefix_anchor":"C","level":1,"prior_prefix":"B"}},"ancestry":[{"id":51378,"edition_id":2,"name":"Commonwealth Health Research Board and Fund; Christopher Reeve Stem Cell Research Fund","identifier":"5.3","label":"chapter","depth":2,"order_by":8,"parent_id":51343,"metadata":{"child_laws":10,"child_structures":0},"date_created":"2026-08-02 02:41:28","date_modified":"2026-08-02 12:32:22","permalink":{"id":1430517,"object_type":"structure","relational_id":51378,"identifier":"5.3","token":"32.1\/5.3","url":"\/32.1\/5.3\/","edition_id":2,"permalink":0,"preferred":1}},{"id":51343,"edition_id":2,"name":"Health","identifier":"32.1","label":"title","depth":1,"order_by":75,"parent_id":null,"metadata":{"child_laws":857,"child_structures":128},"date_created":"2026-08-02 02:40:53","date_modified":"2026-08-02 12:32:12","permalink":{"id":1428101,"object_type":"structure","relational_id":51343,"identifier":"32.1","token":"32.1","url":"\/32.1\/","edition_id":2,"permalink":0,"preferred":1}}],"structure_contents":[{"id":359154,"structure_id":51378,"section_number":"32.1-162.23","catch_line":"Commonwealth Health Research Board established","url":"\/32.1-162.23\/","token":"32.1\/5.3\/32.1-162.23","metadata":false},{"id":359155,"structure_id":51378,"section_number":"32.1-162.24","catch_line":"Duties of the Board","url":"\/32.1-162.24\/","token":"32.1\/5.3\/32.1-162.24","metadata":false},{"id":359156,"structure_id":51378,"section_number":"32.1-162.25","catch_line":"Powers of the Board","url":"\/32.1-162.25\/","token":"32.1\/5.3\/32.1-162.25","metadata":false},{"id":359157,"structure_id":51378,"section_number":"32.1-162.26","catch_line":"Conditions and restrictions on financial assistance","url":"\/32.1-162.26\/","token":"32.1\/5.3\/32.1-162.26","metadata":false},{"id":359158,"structure_id":51378,"section_number":"32.1-162.27","catch_line":"Cooperation with other agencies","url":"\/32.1-162.27\/","token":"32.1\/5.3\/32.1-162.27","metadata":false},{"id":359159,"structure_id":51378,"section_number":"32.1-162.28","catch_line":"Commonwealth Health Research Fund established; administration","url":"\/32.1-162.28\/","token":"32.1\/5.3\/32.1-162.28","metadata":false},{"id":359160,"structure_id":51378,"section_number":"32.1-162.29","catch_line":"Form and audit of accounts and records","url":"\/32.1-162.29\/","token":"32.1\/5.3\/32.1-162.29","metadata":false},{"id":359162,"structure_id":51378,"section_number":"32.1-162.30","catch_line":"Annual report","url":"\/32.1-162.30\/","token":"32.1\/5.3\/32.1-162.30","metadata":false},{"id":359163,"structure_id":51378,"section_number":"32.1-162.31","catch_line":"Christopher Reeve Stem Cell Research Fund","url":"\/32.1-162.31\/","token":"32.1\/5.3\/32.1-162.31","metadata":false},{"id":359164,"structure_id":51378,"section_number":"32.1-162.31:1","catch_line":"Florence Neal Cooper Smith Sickle Cell Research Endowment Fund","url":"\/32.1-162.31_1\/","token":"32.1\/5.3\/32.1-162.31_1","metadata":false}],"previous_section":{"id":359163,"structure_id":51378,"section_number":"32.1-162.31","catch_line":"Christopher Reeve Stem Cell Research Fund","url":"\/32.1-162.31\/","token":"32.1\/5.3\/32.1-162.31","metadata":false},"metadata":false,"official_url":"https:\/\/law.lis.virginia.gov\/vacode\/32.1-162.31:1\/","history_text":"

This law was first created in 2025. The record of its establishment is cataloged in chapter 415<\/a> of that year\u2019s edition of \u201cActs of Assembly,\u201d the annual state publication listing all changes made to the Code of Virginia in that year.<\/p>","references":false,"refers_to":false,"permalink":{"id":1430555,"object_type":"law","relational_id":359164,"identifier":"32.1-162.31:1","token":"32.1\/5.3\/32.1-162.31_1","url":"\/32.1-162.31_1\/","edition_id":2,"permalink":0,"preferred":1},"url":"\/32.1-162.31_1\/","token":"32.1\/5.3\/32.1-162.31_1","dublin_core":{"Title":"Florence Neal Cooper Smith Sickle Cell Research Endowment Fund","Type":"Text","Format":"text\/html","Identifier":"\u00a7 32.1-162.31:1","Relation":"Code of Virginia"},"html":"\n\t\t\t\t\t\t

A.<\/span> From such funds as may be appropriated by the General Assembly and any gifts, grants, or donations from public or private sources, there is created in the state treasury a special, nonreverting, revolving, and permanent fund to be known as the Florence Neal Cooper Smith Sickle Cell Research Endowment Fund. The Fund shall be established on the books of the Comptroller and shall be administered and implemented by the Board<\/span> in accordance with the provisions of this section. All funds appropriated for the Fund and any grants, donations, or other assistance provided shall be paid into the state treasury and credited to the Fund. Interest earned on moneys in the Fund shall remain in the Fund and be credited to it. Any moneys remaining in the Fund, including interest thereon, at the end of each fiscal year shall not revert to the general fund but shall remain in the Fund. Moneys in the Fund shall be used solely for the purpose of making grant payments pursuant to this section. Expenditures and disbursements from the Fund shall be made by the State Treasurer on warrants issued by the Comptroller upon written request signed by the chairman or vice-chairman of the Board<\/span>. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

B.<\/span> Moneys in the Fund shall be used solely to support medical and biomedical sickle cell disease research conducted in institutions of higher education in the Commonwealth that relates to the causes and cures of sickle cell disease. <\/i><\/a><\/p><\/section>\n\t\t\t\t\t\t

C.<\/span> Any appropriations, grants, donations, or other assistance provided pursuant to this section shall be awarded in accordance with the Board<\/span>’s specific criteria and procedures, requirements for submission of research proposals, and evaluation mechanisms established pursuant to this chapter. However, no requirement for matching funds shall apply to the appropriations, grants, donations, or other assistance awarded to the Fund, and the leveraging of funds is incidental to the support provided under this section. The appropriations, grants, donations, or other assistance provided pursuant to this section may, upon demonstrating a reasonable justification to the Board<\/span>’s satisfaction, be awarded to support sickle cell disease research that is not eligible for federal research funds through the National Institutes of Health. No moneys from the Fund may be provided to any entity that conducts human sickle cell disease research from stem cells obtained from human embryos or for conducting such research; however, research conducted using stem cells other than embryonic stem cells may be funded. <\/i><\/a><\/p><\/section>","plain_text":" CODE OF VIRGINIA\n\nFLORENCE NEAL COOPER SMITH SICKLE CELL RESEARCH ENDOWMENT FUND (\u00a7\n32.1-162.31:1)\n\nA. From such funds as may be appropriated by the General Assembly and any gifts,\ngrants, or donations from public or private sources, there is created in the\nstate treasury a special, nonreverting, revolving, and permanent fund to be\nknown as the Florence Neal Cooper Smith Sickle Cell Research Endowment Fund. The\nFund shall be established on the books of the Comptroller and shall be\nadministered and implemented by the Board in accordance with the provisions of\nthis section. All funds appropriated for the Fund and any grants, donations, or\nother assistance provided shall be paid into the state treasury and credited to\nthe Fund. Interest earned on moneys in the Fund shall remain in the Fund and be\ncredited to it. Any moneys remaining in the Fund, including interest thereon, at\nthe end of each fiscal year shall not revert to the general fund but shall\nremain in the Fund. Moneys in the Fund shall be used solely for the purpose of\nmaking grant payments pursuant to this section. Expenditures and disbursements\nfrom the Fund shall be made by the State Treasurer on warrants issued by the\nComptroller upon written request signed by the chairman or vice-chairman of the\nBoard.\n\nB. Moneys in the Fund shall be used solely to support medical and biomedical\nsickle cell disease research conducted in institutions of higher education in\nthe Commonwealth that relates to the causes and cures of sickle cell disease.\n\nC. Any appropriations, grants, donations, or other assistance provided pursuant\nto this section shall be awarded in accordance with the Board’s specific\ncriteria and procedures, requirements for submission of research proposals, and\nevaluation mechanisms established pursuant to this chapter. However, no\nrequirement for matching funds shall apply to the appropriations, grants,\ndonations, or other assistance awarded to the Fund, and the leveraging of funds\nis incidental to the support provided under this section. The appropriations,\ngrants, donations, or other assistance provided pursuant to this section may,\nupon demonstrating a reasonable justification to the Board’s satisfaction,\nbe awarded to support sickle cell disease research that is not eligible for\nfederal research funds through the National Institutes of Health. No moneys from\nthe Fund may be provided to any entity that conducts human sickle cell disease\nresearch from stem cells obtained from human embryos or for conducting such\nresearch; however, research conducted using stem cells other than embryonic stem\ncells may be funded.\n\nHISTORY: 2025, c. 415.","edition":{"id":2,"name":"2026","slug":"2026","date_created":"2026-07-16 18:40:23","date_modified":"2026-08-02 15:14:36","current":1,"order_by":2,"last_import":"2026-08-02 12:37:30"}}